Logo

Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Share this

Galapagos Reports First Patients Dosing with GLPG3970 (Toledo Compound) for Psoriasis

Shots:  

  • The company has reported the first patient dosing in the P-I CALOSOMA study assessing the safety- tolerability- PK/PD of GLPG3970 single & multiple ascending doses in up to 52 adult healthy male subjects. The therapy will now be evaluated in 25 patients with moderate to severe psoriasis for 6wks.
  • Galapagos is also evaluating the potential of GLPG3970 in the P-II SEA TURTLE study for patients with mod. to sev. active UC and in P-II LADYBUG study for patients with severely active RA who had an inadequate response to MTX
  • Galapagos plans to unveil the novel Toledo target class and will share GLPG3970 P-I data at its inaugural Toledo Roundtable to be held virtually on Oct 27- 2020

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: European Technology


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions